Alaunos Therapeutics, Inc.

Alnara Therapeutics is a preclinical-stage biopharmaceutical company developing new, orally administered small-molecule treatments for obesity and related metabolic disorders, including metabolic dysfunction-associated steatotic liver disease (MASLD). The company's approach is non-hormonal and non-incretin, differing from hormone-based treatments like GLP-1 drugs. On March 2, 2026, Alnara Therapeutics announced positive preclinical proof-of-concept data for ALN1003 from two studies using a standard diet-induced obesity (DIO) mouse model in male C57BL/6 mice on a high-fat diet (60% of calories from fat). These studies showed dose-dependent body weight loss with favorable body composition changes, reductions in liver weight, and improvements in liver function and metabolic biomarkers. Alnara Therapeutics was previously a clinical-stage oncology-focused cell therapy company. The company has not generated any product revenue and has incurred significant net losses since its inception, reporting a net loss of $4.2 million for the year ended December 31, 2025, and an accumulated deficit of $924.6 million as of that date. The small molecule oral obesity and metabolic disorders program is internally developed and focuses on discovering and developing novel, orally administered therapeutics with a non-hormonal mechanism of action, distinct from other pipeline therapies exploring hormonal pathways such as amylin or dual GIP/GLP-1 receptor agonism.